Companies Dominating the Cerebral Artery Syndrome Treatment Landscape
- Bristol Myers Squibb
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Athersys, Inc.
- Janssen Pharmaceuticals, Inc
- Royal Philips
- AstraZeneca plc
Browse Key Market Insights with Data Illustration:
In the News
- The FDA has granted Fast Track Designation for all three of the potential Bristol Myers Squibb (NYSE: BMY) in collaboration with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson and Johnson (Janssen), announced that all three prospective indications for milvexian, an investigational oral factor XIa (FXIa) inhibitor, have now been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). The designations cover all three indication-seeking studies within the Phase 3 Librexiadevelopment program, which are all dosing patients. indications of milvexian, an investigational oral factor XIa (FXIa) inhibitor, to Bristol Myers Squibb (NYSE: BMY) in partnership with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson and Johnson (Janssen).
- Following a Type B meeting with the U.S. Food & Drug Administration (FDA), Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine firm developing MultiStem® (invimestrocel) for critical care applications, announced proposed modifications to its MASTERS-2 clinical trial protocol. The meeting, which took place on March 21, 2023, covered the standard of care as well as Athersys' proposed modifications, which aim to establish primary and secondary endpoints that best reflect the company's belief of the full potential benefit of MultiStem treatment for patients with acute, moderate-to-severe ischemic stroke.
